Manitoba, Canada — July 30, 2025 — Canadians seeking advanced weight loss treatments now have a new, more affordable option. Online pharmacy fulfillment service DutyFreeMeds.com has announced the availability of Zepbound (tirzepatide), the groundbreaking obesity medication recently approved for use in Canada.
Developed by Eli Lilly, Zepbound has been making headlines for its clinical success in the United States and is now recognized as a highly effective treatment for obesity. The medication works by activating both GLP-1 and GIP receptors to reduce appetite and support weight loss, with clinical studies showing up to 22.5% body weight reduction in patients.
“We’re proud to provide Canadians with affordable access to Zepbound,” said Hank Popeil, spokesperson for DutyFreeMeds.com. “With rising demand and limited availability through traditional channels, our platform plays a key role in making this important treatment more accessible.”
While Zepbound remains costly in the U.S.—often exceeding $1,000 per month without insurance—DutyFreeMeds.com offers a cost-effective alternative. Medications are sourced from licensed international pharmacies, with no hidden fees or prescription markups, allowing both Canadian and American patients to access high-quality treatments at significantly lower prices.
About Duty Free Meds
Based in Manitoba, Canada, Duty Free Meds is a trusted online prescription fulfillment service committed to helping patients access affordable medications. Working in collaboration with licensed pharmacies and certified healthcare professionals, the platform ensures all products meet Health Canada quality and safety standards. Thousands of customers across North America rely on Duty Free Meds for secure, cost-effective, and convenient medication delivery.
Media Contact:
Hank Popeil
Spokesperson, Duty Free Meds
Website: www.dutyfreemeds.com